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Summary
 Background: Tacrolimus is a substrate of cytochrome P-450 (CYP) 3A enzyme and of the drug 
transporter ABCB1. We have investigated the effects of possible relevant CYP3A5 
and ABCB1 single nucleotide polymorphisms (SNPs) present in both donors and 
recipients on tacrolimus blood levels achieved in a population of 32 Caucasian 
liver transplant patients.
 Material/Methods: At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) 
and trough blood levels (C0) were determined. Polymerase chain reaction fol-
lowed by restriction fragment length polymorphism analysis was used for gen-
otyping CYP3A5*3 [6986A>G] as well as ABCB1 at exons 21 [2677G>T] and 26 
[3435C>T].
 Results: 87.5% of the population showed a CYP3A5*3/*3 genotype. For the ABCB1 SNPs, 
in the case of 3435C>T the total frequency observed for the allelic variant was 
50%. For the 2677G>T, the total frequency of the allelic variant was 12.5%, low-
er than in other Caucasian populations and without any signifi cant linkage with 
3435C>T. At 3 and 6 months after transplantation, tacrolimus dose requirements 
were signifi cantly higher in patients receiving a liver with one copy of the *1 al-
lele compared to those homozygous for the *3 allele (0.111±0.057 vs. 0.057±0.030 
[P<0.05] at 3 month and 0.086±0.051 vs. 0.044±0.025 [P<0.05] at 6 month). For 
the recipients’ genotypes, the presence of at least one *1 copy tended, though not 
statistically signifi cantly, to increase tacrolimus doses. With regard to the ABCB1 
SNPs, they did not show any infl uence on tacrolimus dosing requirements.
 Conclusions: Pharmacogenetic analysis of CYP3A5 in the donor could contribute to determine 
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BACKGROUND
Tacrolimus is an immunosuppressant widely 
used in liver transplant patients. Due to its nar-
row therapeutic index and high inter-and intra-
individual pharmacokinetic variability, the ad-
ministration regimens of this drug need to be 
closely monitored [1]. In fact, achieving the de-
sired target blood concentrations immediately 
after transplantation is of critical importance to 
avoid rejection or excessive immunosuppression 
and to limit important dose-related adverse reac-
tions such as nephrotoxicity, neurotoxicity and 
hyperglycemia [1].
To date the most widely used parameter for the 
therapeutic monitoring of tacrolimus is its trough 
whole blood concentration (C0), that is measured 
12 hours after the dose administration and cor-
relates well with the area under the concentra-
tion-time curve [2,3].
Many factors of pharmacokinetic and pharma-
codynamic nature may infl uence the activity of 
the drug [1,2,4,5]. Also the genetic background 
may infl uence the inter-individual variability in 
the pharmacokinetics of tacrolimus [6].
After oral administration, tacrolimus has limited 
bioavailability (~25%, but it can vary from 4% to 
93%) and is extensively metabolized by the ox-
idative enzymes cytochromes P4503A (CYP3A4 
and CYP3A5) in the intestinal wall and liver [1,7]. 
CYP3A constitute the most abundant group of 
the cytochrome P450 family and are responsi-
ble for the metabolism of more than half of clin-
ically used drugs [8,9]. Previous studies have 
shown that a single nucleotide polymorphism 
(SNP), that is 6986A>G at intron 3, correlates 
with CYP3A5 protein production and enzyme 
activity [10]. Individuals with at least one wild-
type allele (*1) express hepatic and intestinal 
CYP3A5, whereas the subjects homozygous for 
the mutant variant (*3/*3) do not present a func-
tional protein [10,11]. Accordingly, several stud-
ies have indicated that this CYP3A5 SNP can be 
associated with changes in tacrolimus dose re-
quirements [12–14].
In addition, similarly to other drugs commonly 
used in transplantation, tacrolimus is also a sub-
strate of P-glycoprotein (P-gp), a membrane drug 
effl ux transporter encoded by the multi- drug re-
sistance ABCB1 (MDR1) gene [15]. P-gp is present 
in several human tissues and organs like the in-
testine, adrenal gland, kidney, liver, blood-brain 
barrier, placenta, lymphocytes, ovary and testis 
[16]. It infl uences the disposition of several xe-
nobiotics by limiting their absorption from the 
gut lumen and increasing their biliary and uri-
nary excretion [17,18].
It has been suggested that some SNPs of the 
ABCB1 gene, like 2677G>T at exon 21 and 
3435C>T at exon 26, may cause altered P-gp ex-
pression and function [19,20]. Although 3435C>T 
is a silent polymorphism, that does not result in an 
amino acid change in the encoded protein, it may 
be in linkage disequilibrium with other function-
al polymorphisms of the ABCB1 gene, including 
2677G>T, which causes a serine-alanine substitu-
tion and results in a low expression of intestinal 
P-gp [21]. In addition, recent data have suggested 
that the 3435C>T substitution may reduce ABCB1 
mRNA stability in the liver [22]. People with the 
2677GG or 3435CC genotypes would have greater 
function of the drug transporter associated with 
lower tacrolimus bioavailability and level/dose ra-
tios [21,23,24]. However, the conclusions drawn 
so far on the real importance of ABCB1 SNPs on 
tacrolimus or cyclosporine pharmacokinetics are 
largely controversial [14,21,23–26].
Importantly, the allele frequencies of the afore-
mentioned CYP3A5 and ABCB1 SNPs can widely 
differ among ethnic groups [27–29]. The objec-
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tive of this exploratory study was to analyze the 
possible infl uence of these SNPs on tacrolimus 
dose requirements in a population of Caucasian, 
mainly Sicilian, liver transplant patients.
MATERIAL AND METHODS
Subjects
A total of 32 subjects (24 males, 8 females) 
who underwent liver transplantation at the 
Mediterranean Institute for Transplantation and 
Advanced Specialized Therapies (ISMETT) and 
their respective donors were consecutively in-
cluded in this study. The average age of the liv-
er transplant recipients was 53.53±12.38 (15–66) 
years; all them were Caucasians and in particu-
lar 29 (90.6%) were Sicilians. The average age of 
the transplant donors was 39.25±18.99 (15–82); 
13 were males and 19 females and all Caucasians 
(65.6% Sicilians). After transplantation, the re-
cipients were treated with tacrolimus, alone or 
in combination with steroids (mostly during the 
fi rst month) and/or mycophenolate mofetil.
They were checked to make sure that they were 
not taking any drug known to interact with tac-
rolimus. The average initial tacrolimus dose was 
0.015 mg/kg every 12 hours subsequently ad-
justed according to the whole blood trough (C0) 
levels. The target C0 level was set between 5 and 
12 ng/mL.
Body weight, laboratory data (including albu-
min, serum creatinine and liver function tests), 
tacrolimus dosage (mg/kg/day) and C0 levels 
were recorded at 1, 3 and 6 months after trans-
plantation. Blood samples for tacrolimus C0 lev-
els determinations were drawn just prior to the 
morning dose. Whole blood tacrolimus concen-
trations were measured by EMIT 2000 immu-
noassay (DADE Behring, Hilden, Germany). 
The dose-adjusted C0 level (L/D) was calculat-
ed by dividing the tacrolimus C0 level by the cor-
responding 24 h dose. The information thus ob-
tained was the tacrolimus dose needed to obtain 
a given C0 level.
The protocol was approved by the Institutional 
Review Board of ISMETT and informed consent 
was obtained for all patients.
Genotype identifi cation
Recipient and donor genotypes were determined 
by analysing 200 μL of EDTA-anticoagulated 
blood. Genomic DNA was extracted using the 
QIAmp DNA Mini Kit (Qiagen, Crawley, UK). 
The PCR-RFLP (polymerase chain reaction – 
restriction fragment length polymorphism) as-
say was then applied to identify the CYP3A5*3, 
2677G>T and 3435C>T genetic polymorphisms. 
We used 150 ng of genomic DNA for PCR am-
plifi cation.
The forward primer for CYP3A5*3 was 5’-CAT CAG 
TTA GTA GAC AGA TGA-3’ and the reverse prim-
er was 5’-GGT CCA AAC AGG GAA GAA ATA-3’; 
the forward primer for 2677G>T was 5’-TAC CCA 
TCA TTG CAA TAG CAG-3’ and the reverse prim-
er was 5’-TTT AGT TTG ACT CAC CTT TCT AG-
3’; the forward primer for 3435C>T was 5’-CAT 
GCT CCC AGG CTG TTT AT-3’ and the reverse 
primer was 5’-GTA ACT TGG CAG TTT CAG TG-
3’. PCR was performed in a total volume of 50 μL 
with 40 picomoles of each primer, 0.2 mM dNTP, 
1 X High Fidelity PCR Buffer (600 mM TRIS-SO4 
pH 8.9 and 180 mM NH SO4), 2 mM Mg SO4 and 
1.5 U of Taq DNA polymerase (Platinum Taq High 
Fidelity, Invitrogen, Carlsbad, CA, USA). PCR 
process included initial denaturation at 94°C for 
7 min, followed by 35 cycles of denaturation for 
1 min at 94°C, 35 cycles of annealing for 1 min at 
55°C, and 35 cycles of synthesis for 1 min at 72°C. 
The fi nal extension was carried out for 7 min at 
72°C. The PCR products (10 μL for each samples) 
were analyzed by electrophoresis on 1% agarose 
gel. The enzymatic digestion was performed for 2 
hours at 37°C using specifi c restriction enzymes. 
For CYP3A5*3 we used 15 μL of PCR product and 
10 U of SspI plus 1 X Buffer (50 mM NaCl, 100 
mM TRIS-HCl, 10 mM MgCl2 and 0.025% Triton 
X-100) in a total volume of 20 μL; for 2677G>T, 
we used 15 μL of PCR product and 20 U of XbaI 
plus 1 X Buffer (50 mM NaCl, 10 mM TRIS-HCl, 
10 mM MgCl2 and 1 mM DTT) in a total volume 
of 20 μL; and for 3435C>T we used 10 μL of PCR 
product and 10 U of DpnII plus 1 X Buffer (100 
mM NaCl, 50 mM BIS TRIS-HCl, 10 mM MgCl2 
and 1 mM dithiothreitol) in a total volume of 15 
μL. The digestion products were then subjected 
to 3% agarose gel electrophoresis and detected 
by staining with ethidium bromide.
Statistical analysis
All values were expressed as means ± SD and the 
two-tailed Mann-Whitney U test was employed 
to determine the difference in continuous val-
ues among groups. The c2-square test was used 
to analyse differences between Sicilian and non-
Sicilian subjects.
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The allele and genotype frequencies of the 
CYP3A5 and ABCB1 polymorphisms were assessed 
for deviation from the Hardy-Weinberg equilibri-
um using the c2-square test. P values <0.05 were 
considered statistically signifi cant.
RESULTS
Frequency of CYP3A5 and ABCB1 variants in 
liver transplant recipients and donors
As shown in Table 1, among the 32 liver transplant 
recipients involved in the study, CYP3A5*3/*3 
genotype was observed in 29 (90.7%) cases, 
CYP3A5*1/*3 in 2 (6.2%) cases and CYP3A5*1/*1 
in 1 (3.1%) case. For the corresponding do-
nors, CYP3A5*/3*3 genotype was present in 27 
(84.4%) cases and CYP3A5*1/*3 in 5 (15.6%) 
cases. Overall, the frequency of CYP3A5*/3*3 
was 87.5% (56/64 subjects), that of *1/*3 10.9% 
(7/64 subjects) and that of *1/*1 1.6% (1/64 
subjects). The total allelic frequency was 93% 
for CYP3A5*3 and 7% for CYP3A5*1.
As for the ABCB1 SNP at exon 21 (2677G>T), the 
GG and GT genotypes were found in 27 (84.4%) 
and 5 (15.6%) of the transplant recipients, re-
spectively. The GG, GT and TT genotypes were 
found in 23 (71.9%), 7 (21.9%) and 2 (6.2%) of 
the donors, respectively. The overall percentages 
of expression of GG, GT and TT were 78.1, 18.8 
and 3.1, respectively. The total frequency of the 
allelic variant was 12.5%.
For the SNP of ABCB1 at exon 26 (3435C>T), 
among the recipients, the CC, CT and TT geno-
types were observed in 5 (15.6%), 19 (59.4%) and 
8 (25%) cases, respectively. Among the donors, 
the CC, CT and TT genotypes were observed in 
10 (31.2%), 15 (46.8%) and 7 (22%) cases, re-
spectively. The overall percentages of expression 
were 23.4, 53.2 and 23.4 for the wild-type, heter-
ozygous and homozygous mutated genotypes, re-
spectively. The total frequency observed for the 
allelic variant was 50%.
The data showed no signifi cant association 
between the two ABCB1 polymorphisms. The 
CYP3A5 and ABCB1 genotype frequencies were 
not signifi cantly different from those predicted 
by the Hardy-Weinberg equilibrium, thus indi-
cating the reliability of the genotype determi-
nations.
Relationship of CYP3A5 and ABCB1 SNPs 
to tacrolimus C0 blood levels and dose 
requirements
At 1, 3 and 6 months after liver transplant the 
average tacrolimus doses (mg/kg/day) were 
0.083 (0.025–0.157), 0.066 (0.014–0.21) and 
0.051 (0.006–0.177), respectively. Table 2 shows 
the tacrolimus doses needed to obtain a given 
blood C0 level according to the donors’ and re-
cipients’ genotypes. The data (Table 2) show an 
infl uence of the donors’ genotypes on tacrolimus 
dose requirements only for the CYP3A5 gene. In 
fact, 3 and 6 months after transplantation, the 
daily doses of tacrolimus needed to reach target 
blood levels were signifi cantly (P<0.05) higher 
in the patients receiving a liver with one copy of 
the *1 allele compared to those homozygous for 
Recipients’ 
genotype
Allelic status n. of pts
Donors’
genotype
Allelic status n. of pts
Total percentage 
of expression
CYP 3A5*3 *3/*3  29 (90.7%) CYP3A5*3 *3/*3  27 (84.4%)  87.5 (56/64)
*1/*3  2 (6.2%) *1/*3  5 (15.6%)  10.9 (7/64)
*1/*1  1 (3.1%) *1/*1 –  1.6 (1/64)
ABCB1 2677G>T
(Exon 21)
G/G  27 (84.4%)
ABCB1 2677G>T
(Exon 21)
G/G  23 (71.9%)  78.0 (50/64)
G/T  5 (15.6%) G/T  7 (21.9%)  19.0 (12/64)
T/T – T/T  2 (6.2%)  3.0 (2/64)
ABCB1 3435C>T
(Exon 26)
C/C  5 (15.6%)
ABCB1 3435C>T
(Exon 26)
C/C  10 (31.2%)  23.4 (15/64)
C/T  19 (59.4%) C/T  15 (46.8%)  53.2 (34/64)
T/T  8 (25.0%) T/T  7 (22.0%)  23.4 (15/64)
Table 1. Distribution of CYP3A5 and ABCB1 genotypes in liver transplant donors and recipients.






















































































































































































































































































































































































































Table 2. Relationship between  genotypes, blood levels and tacrolimus doses.
* statistically signifi cant values (P<0.05, Mann-Whitney U-test).
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the *3 allele and this in absence of signifi cant 
variations of tacrolimus C0 levels between the 
two groups. A similar, but statistically non-signif-
icant, trend was observed also one month after 
transplantation (Table 2); it can be seen that at 
that time the tacrolimus C0 levels were substan-
tially lower in the patients receiving livers with 
*1/*3 (6.51±2.17 ng/mL) rather than with *3/*3 
(8.07±3.52 ng/mL), thus possibly hindering a 
stronger effect of the donors’ genotype on tac-
rolimus dose requirements.
Also for the recipients’ genotypes, the presence 
of at least one *1 copy tended to increase tac-
rolimus doses and to lower dose-adjusted C0, 
though the differences with respect to the *3/*3 
genotypes were not statistically signifi cant in any 
of the time intervals considered (Table 2). The 
data of Table 2 also show that there were no sig-
nifi cant infl uences of the ABCB1 2677G>T or 
3435C>T SNPs, present either in the donors’ or 
in the recipients’ genotypes, on tacrolimus dos-
ing requirements during the fi rst six months af-
ter transplantation.
This was seen also when the possible effects of 
the same ABCB1 SNPs were analysed taking into 
account the presence or not of the *1 CYP3A5 
allele in the donors’ or in the recipients’ geno-
types (not shown).
Finally, also according to previous reports [30–34], 
tacrolimus dosing requirements were not differ-
ent according to the sex of either the donors or of 
the recipients (not shown). It is debated whether 
co-exposure to steroids may infl uence tacrolimus 
clearance at CYP3A level [35–37]; however, in this 
series we did not fi nd any signifi cant differences 
in the tacrolimus dosages needed by the patients 
receiving steroids with respect to those steroid-
free (analysis not shown), also when the differ-
ent genotypes of the recipients and of the donors 
were considered. This may depend on the fact 
that steroids, according to the patient’s clinical 
condition and in the absence of rejection, were 
rapidly tapered and then discontinued during the 
fi rst month after transplantation [5,33].
DISCUSSION
Analysis of CYP3A5 and ABCB1 SNPs revealed 
a high overall percentage of homozygosity for 
the CYP3A5*3 variant (6986A>G at intron 3) 
in the present population composed entirely of 
Caucasian subjects. This result is in good agree-
ment with other reports which have indicated 
that up to 90% of Caucasians have such geno-
type [10,38–40]; in other races, in particular in 
Africans or African-Americans, the percentage of 
subjects with the *3/*3 genotype is much lower 
(about 30%) [10,38,40,41]. As for the ABCB1 SNP 
2677G>T at exon 21, we observed a total frequen-
cy of the allelic variant T (12.5%) lower than that 
(40–50%) observed in other Caucasian popula-
tions [28,42–44] and more similar to that (13%) 
of African-American individuals [27,29,44]. This 
fi nding might perhaps represent a peculiarity 
of our population mainly made up of Sicilians; 
however the difference in the frequencies of T 
between Sicilians (9%, n=50) and non-Sicilians 
(25%, n=14) was not statistically signifi cant.
As for the ABCB1 3435C>T SNP at exon 26, the 
overall frequency of the allelic variant T was 
50%, in accordance with other studies which 
have reported percentages in Caucasians be-
tween 33% and 65% [42,44,45]. In our popu-
lation there was not the linkage between the 
2677G>T and 3435C>T SNPs suggested by oth-
er authors [21,44,46].
Considering the relationship between genotypes 
and tacrolimus dose requirements, it has been 
shown that subjects homozygous for the *3 var-
iant do not express functional CYP3A5 and ex-
hibit lower clearance of the drug [11,29,47,48]. 
For this reason, they require lower doses of tac-
rolimus to reach target blood levels compared 
with the subjects with at least one *1 allele (ex-
pressors). Results of this kind have been found 
checking the genotypes of kidney, heart and lung 
transplanted patients [13,49–51]. As for liver 
transplants, our data confi rm those of other au-
thors who have indicated the main importance 
of the liver donors’ genotype with regard to the 
expression of CYP3A5 [52]. They trend to sug-
gest also some infl uence of the recipients’ geno-
type, implying the possible role that CYP3A5 may 
play also in extrahepatic tissues like the intesti-
nal wall, as others have reported [53].
With regard to ABCB1 SNPs, previous studies have 
not produced consistent results: some authors 
have indicated that the subjects homozygous for 
the variant allele 3435T at exon 26 present a re-
duction in intestinal P-gp, with an effect on the 
bioavailability of P-gp substrates like cyclosporine 
and tacrolimus [19,21,24,50,54]. Nevertheless, 
several other studies performed in kidney, lung 
and heart transplant patients have excluded that 
ABCB1 genetic polymorphisms play any relevant 
role in determining cyclosporine or tacrolimus 
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pharmacokinetics [14,25,55–59]. Though our 
present data need to be corroborated in a larg-
er population of patients, they are in agreement 
with the latter conclusion, since there were no 
signifi cant infl uences of the ABCB1 2677G>T or 
3435C>T SNPs, present in the recipients’ or also 
in the donors’ genotypes, on tacrolimus dosing 
requirements during the fi rst six months after 
transplantation.
Finally, we observed a very wide variability of the 
tacrolimus doses required to reach target blood 
levels even among the patients carrying the same 
genotype (in particular of CYP3A5, whose SNP ap-
peared to be functionally active) and with a high 
overlap of the values between the wild-type and 
mutant genotypes. This further underlines that 
genetic polymorphism is only one of the possi-
ble factors which may infl uence tacrolimus phar-
macokinetics [34,60–62].
CONCLUSIONS
The results of the present study suggest that phar-
macogenetic analysis cannot substitute thera-
peutic drug monitoring, even though genotyp-
ing the CYP3A5*3 polymorphism of the donor 
can represent a useful tool to evaluate the appro-
priate initial dosage of tacrolimus in liver trans-
plant patients.
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